Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in multidistrict litigation against drug makers and others over their alleged role in the opioid crisis. The company said 47 state and territorial attorneys general support the agreement, in which its specialty generics subsidiaries would file for Chapter 11 bankruptcy. Under the proposed settlement, subject to court approval and other conditions, Mallinckrodt would pay $1.6 billion in structured payments after the subsidiaries emerged from Chapter 11, the majority going to a trust that would in part cover the costs of opioid addiction treatment and related efforts, the company said.   

Related News Articles

Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…
Headline
States expanding Medicaid eligibility under the Affordable Care Act had a 6% lower rate of opioid overdose deaths by county after the expansion than did other…
Headline
A new report from the National Academies of Sciences, Engineering, and Medicine recommends two frameworks that medical professional societies, health care…
Headline
The opioid stewardship collaborative — a free yearlong, mentored initiative for hospitals and health systems that includes virtual coaching and…